There has been great interest in targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR) as a means of augmenting the insulinotropic and anti-obesity action of glucagon-like peptide-1 receptor (GLP-1R) agonists. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.